HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK)
HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) Produktliste
- Attribut
Protein (2)
- Produktbibliothek
Online (2)
- Spezies
Human (2)
- Etikett
His Tag & Avi Tag (1)His Tag (1)
- Marker
Biotin-labeled (1)PE Labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Complex Protein (Monomer, MALS verified) |  |  |  In den Warenkorb legen | ||
| Human | HEK293 | PE-Labeled Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Tetramer Protein | In den Warenkorb legen |
Gesamtmenge2
- 1
HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) Molekülhintergrund
The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Biotinylated Human HLA-A*0301 KRASG12V (VVGAVGVGK) complex protein is a complex of HLA-A*0301 of the MHC Class I, B2M, and VVGAVGVGK peptide of the KRASG12V.
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| DNDI-6148 | DNDI-6148 | Phase 1 Clinical | Drugs For Neglected Diseases Initiative | Infections; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral | Details |
| AN-3661 | AN-6426; AN-3661 | Phase 1 Clinical | Anacor Pharmaceuticals Inc | Malaria | Details |
- Produktliste
- Klinische Arzneimittelinformation